IntraMed - Artículos - Hormonoterapia prolongada en la posmenopausia
Riesgo de cáncer de endometrio | 31 OCT 07
Hormonoterapia prolongada en la posmenopausia
Los resultados de este estudio avalan que la hormonoterapia no solo no aumenta el riesgo de cáncer de endometrio, sino que el mismo puede verse disminuído.
(1)
Autor: Dres. Jennifer A. Doherty, Kara L. Cushing-Haugen, Babette S. Saltzman, Lynda F. Voigt, Deirdre A. H Fuente: Traducción y resumen objetivo: Dra. Marta Papponetti. Especialista en Medicina Interna. Am J Obstet Gynecol 2007;197:139.e1-139.e7
INDICE:  1. Desarrollo | 2. Referencias
Referencias

1. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.
2. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
3. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47-53.
4. Coope J, Thomson JM, Poller L. Effects of “natural oestrogen” replacement therapy on menopausal symptoms and blood clotting. BMJ 1975;4:139-43.
5. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 2003;290:1729-38.
6. Cook LS, Weiss NS. Endometrial cancer. In: Goldman MB, Hatch MC, editors. Women & health. London: Academic Press; 2000:916-31.
7. Beresford SA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997;349:458-61.
8. Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999;91:1131-7.
9. Beral V, Bull D, Reeves G, Million Women Study collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005;365:1543-51.
10. Pike MC, Peters RK, Cozen W, et al. Estrogen- progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997;89:1110-6.
11. Strom BL, Schinnar R, Weber AL, et al. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer. Am J Epidemiol 2006;164:775-86.
12. Newcomb PA, Trentham-Dietz A. Patterns of postmenopausal progestin use with estrogen in relation to endometrial cancer (United States). Cancer Causes Control 2003;14:195-201.
13. Jain MG, Rohan TE, Howe GR. Hormone replacement therapy and endometrial cancer in Ontario, Canada. J Clin Epidemiol 2000;53:385-91.
14. Lacey JV, Brinton LA, Lubin JH, Sherman ME. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev 2005;14:1724-31.
15. Hill DA, Weiss NS, Beresford SA, et al. Continuous combined hormone replacement therapy and risk of endometrial cancer.AmJ Obstet Gynecol 2000;183:1456-61.
16. Marchbanks PA, McDonald JA, Wilson HG, et al. The NICHD women’s contraceptive and reproductive experiences study: methods and operational results. Ann Epidemiol 2002;12:213-21.
17. Hankey BF, Ries LA, Edwards BK. The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Biomarkers Prev 1999;8:1117-21.
18. Waksberg J. Sampling methods for random digit dialing. J Am Stat Assoc 1978;73:40-6.
19. Voigt LF, Weiss NS, Chu J, Daling JR, Mc- Knight B, van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991;338:274-7.
20. Jain MG, Rohan TE, Howe GR. Agreement of self-reported use of menopausal hormone replacement therapy with physician reports. Epidemiology 1999;10:260-3.
21. Strom BL, Schinnar R. An interview strategy was critical for obtaining valid information on the use of hormone replacement therapy. J Clin Epidemiol 2004;57:1210-3.
22. Effects of hormone replacement therapy on endometrial histology in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial: the Writing Group for the PEPI trial. JAMA 1996;275:370-5.
23. Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynaecologic cancers and associated   diagnostic procedures: the Women’s Health Initiative randomized trial. JAMA 2003;290:1739-48.
24. Koepsell TD, Weiss NS. Epidemiologic methods: studying the occurrence of illness.NewYork: Oxford University Press; 2003: 328.
25. Reed SD, Voigt LF, Beresford SA, Hill DA, Doherty JA, Weiss NS. Dose of progestin in postmenopausal-combined hormone therapy and risk of endometrial cancer. Am J Obstet Gynecol 2004;191:1146-51.
26. Persson I, Weiderpass E, Bergkvist L, Bergstrom R, Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 1999;10:253-60.
27. Jick SS, Walker AM, Jick H. Estrogens, progesterone, and endometrial cancer. Epidemiology 1993;4:20-4.
28. Brinton LA, Hoover RN. Estrogen replacement therapy and endometrial cancer risk: unresolved issues: the Endometrial Cancer Collaborative group. Obstet Gynecol 1993; 81:265-71.

(1)

Comentarios

Usted debe estar registrado para expresar su opinión. Si ya es usuario de IntraMed o desea registrase como nuevo usuario, ingrese aquí
Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2014